There are 2789 resources available
Invited Discussant 1170O and LBA65
Presenter: Pilar Garrido Lopez
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
No
Presenter: Yelena Janjigian
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Florian Lordick
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Q&A
Presenter: Florian Lordick
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Florian Lordick
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Yes
Presenter: John Reynolds
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Invited Discussant VP3_2021
Presenter: Pasi Jänne
Session: Virtual Plenary Debate
Resources:
Slides
Webcast
Invited Discussant VP7_2021
Presenter: Lisa Carey
Session: Virtual Plenary Debate
Resources:
Slides
Webcast
VP7_2021 - KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Presenter: Peter Schmid
Session: Virtual Plenary Debate
Resources:
Abstract
Slides
Webcast
VP2_2021 - Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
Presenter: Solange Peters
Session: Virtual Plenary Debate
Resources:
Abstract
Slides